Dr. Michiel Rienstra attended medical school at the University of Antwerp, Belgium, received his MD cum laude. Obtained his PhD at the University of Groningen, The Netherlands. He completed his cardiology training at the University Medical Center Groningen, followed by training as device cardiologist. Michiel Rienstra is an Associate Professor at the University of Groningen, and cardiologist at the University Medical Center Groningen, specialized in atrial fibrillation, devices and advanced heart failure. Since 2017, Michiel is clinical director of the Cardiology department, University Medical Center Groningen.
He was awarded with a NWO Rubicon grant in 2009 and went to Harvard Medical School, Massachusetts General Hospital and the Framingham Heart Study for a post-doc on population genetics and epidemiology in 2010-2011. In 2012 he was awarded with the NWO Veni grant for his project on genetics of atrial fibrillation. In 2015 he was awarded with the European Society of Cardiology academic grant for his project on a big data approach in atrial fibrillation. In 2014 the RACE-V program was funded by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation. Michiel is work package 8 principal investigator, and as investigator involved in 3 other work packages, and is assigned by the consortium as young talent. In 2017 the RED-CVD program was funded by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation. Michiel is work package principal investigator, and is assigned by the consortium as young talent.
Since 2012, Dr. Rienstra was co-promotor of 6 PhD students. And he is currently co-promotor and daily supervisor of the current members of the atrial fibrillation research team.
He is fellow of the European Society of Cardiology and the American Heart Association, and Leadership committee member of the Functional Genomics and Translational Biology council. He was 4 years Associate Editor of the European Journal of Heart Failure, and is currently Associate Editor of the (open-access) Frontiers in Cardiovascular Genetics and Systems Medicine. He is reviewer for all important cardiology journals, Lancet and JAMA. Michiel is also board member of the Dutch initiative AF Connect optimizing transmural AF care.
His research focuses on the understanding the susceptibility to atrial fibrillation, and exploring novel management strategies of atrial fibrillation. His research consists of clinical studies to improve atrial fibrillation management, epidemiological studies of atrial fibrillation and its risk factors, genetic studies of atrial fibrillation, and bioinformatic and big data approaches to improve atrial fibrillation risk prediction.